Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 7244Neoplasms 4539Prostatic Neoplasms 3489Colorectal Neoplasms 2940Carcinoma, Non-Small-Cell Lung 2831Lung Neoplasms 2547Leukemia, Myeloid, Acute 1982Pancreatic Neoplasms 1874Multiple Myeloma 1811Carcinoma, Hepatocellular 1733Neoplasm Metastasis 1585Stomach Neoplasms 1502Lymphoma 1457Precursor Cell Lymphoblastic Leukemia-Lymphoma 1435Head and Neck Neoplasms 1435Brain Neoplasms 1373Melanoma 1348Ovarian Neoplasms 1342Leukemia 1303Rectal Neoplasms 1270Recurrence 1255Colonic Neoplasms 1204Glioblastoma 1138Uterine Cervical Neoplasms 1096Lymphoma, Non-Hodgkin 1066Leukemia, Lymphocytic, Chronic, B-Cell 989Esophageal Neoplasms 965Lymphoma, Follicular 936Lymphoma, Large B-Cell, Diffuse 932Squamous Cell Carcinoma of Head and Neck 921

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Interventional × Rubinstein-Taybi Syndrome × Clear all
NCT06740162 2026-02-23

PACE

University of North Carolina, Chapel Hill

Phase NA Recruiting
376 enrolled

Autism Spectrum Disorder, Trisomy 13 Syndrome, Cri-du-Chat Syndrome, De Lange Syndrome, Down Syndrome, Fragile X Syndrome, Intellectual Disability, Motor Activity, Prader-Willi Syndrome, Rubinstein-Taybi Syndrome, WAGR Syndrome, Williams Syndrome, X-Linked Intellectual Disability, Neurodevelopmental Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡